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Abstract: Arginase, a drug target for the treatment of leishmaniasis, is involved in the biosynthesis
of polyamines. Flavonoids are interesting natural compounds found in many foods and some of
them may inhibit this enzyme. The MetIDB database containing 5667 compounds was screened using
an EIIP/AQVN filter and 3D QSAR to find the most promising candidate compounds. In addition,
these top hits were screened in silico versus human arginase and an anti-target battery consisting of
cytochromes P450 2a6, 2c9, 3a4, sulfotransferase, and the pregnane-X-receptor in order to flag their
possible interactions with these proteins involved in the metabolism of substances. The resulting
compounds may have promise to be further developed for the treatment of leishmaniasis.
Keywords: Leishmania; arginase; flavonoid; in silico; screen; anti-target; leishmaniasis; natural
products; pregnane-X-receptor; sulfotransferase; cytochrome P450
1. Introduction
Leishmaniasis, a vector-borne infectious disease, is endemic in 98 countries in parts of the
tropics, subtropics, and in Europe [1–3]. Leishmaniasis can have skin, mucocutaneous, and visceral
presentations caused by 20 different Leishmania parasite species. This is a neglected tropical disease
(NTD) and a major public health problem that currently affects 12 million people with estimated 0.2 to
0.4 million of new visceral leishmaniasis cases and 0.7 to 1.2 million of new cutaneous leishmaniasis
cases each year, globally [1,4]. It is also a severe co-infection with human immunodeficiency virus
infection (HIV), where there is a high chance of developing the full-blown clinical disease with high
relapse and mortality rates [5].
The synthesis of polyamines (PA) is essential for intracellular growth of Leishmania [6]. Arginase
is the first enzyme involved in PA biosynthesis and hydrolyses arginine into ornithine and urea [7].
Blocking arginase can lead to oxidative stress in parasite cells, due to a deficiency in trypanothione
production and thus promote infection control [8]. Leishmania becomes auxotrophic for polyamines
when the arginase gene is deleted, showing the significance of this enzyme for parasite survival [9].
Arginase has two characteristics that are important for a parasite drug target: distinction from the
mammalian target [10] and absolute necessity for the survival of the pathogen [11]. Among individual
infectious diseases, leishmaniasis causes the ninth largest disease burden, but because of a lack of
commercial interest it is still one of the most neglected diseases in terms of drug development [12,13].
There are no vaccines and the control of leishmaniasis primarily depends on chemotherapy. Current
chemotherapies against leishmaniasis are highly toxic, cause side effects, and commonly, drug
resistance. In addition, compliance of patients to therapy is low as treatment is long and expensive [12].
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Development of new effective chemotherapeutic agents for treatment of leishmaniasis is greatly
needed. Natural products are a promising source of low toxicity, efficient, and widely accessible drug
candidates [14]. In addition and very importantly, natural products are a rich source of compounds
with anti-leishmanial activity [15]. Previously, it was reported that alkaloids, phenolic derivatives,
and terpenes are among the most potent anti-leishmanial compound classes [16]. Plant derived
polyphenols are reported as important sources of Leishmania arginase inhibitors [17]. Evidence
suggests that arginase is the most investigated enzyme in studies involving flavonoid compounds
as enzymatic inhibitors for Leishmania [18]. The bioactive compounds of C. pachystachya that inhibit
Leishmania arginase were characterized as glucoside flavonoids [19]. Previous research on the activity
of natural compounds as arginase inhibitors provided novel structures that could be used for designing
pharmaceutical compounds and might allow a dietary approach to diseases associated with arginase
pathway regulation [17,20].
An important part of any treatment with a compound is the selectivity the compound has for its
target and the avoidance of toxic and side-effects. Anti-targets are off-targets that a compound would
ideally have a specific form of interaction with, in addition to the target [21]. A set of anti-targets
that are present in the metabolism of substances has been developed and has found use as an in silico
protein-ligand interaction assessment [22,23].
In this work, we performed a virtual screening protocol that considers both short-and long-range
interactions between interacting molecules. The long-range interactions are characterized by the
parameters—the average quasi valence number (AQVN) and the electron-ion interaction potential
(EIIP) [24,25]. First, the EIIP/AQVN filter was applied for in silico screening of the MetIDB database
for anti-leishmanial arginase inhibitors and then followed by 3D QSAR. The database of flavonoid
compounds was then filtered and assessed for its binding interactions with Leishmania arginase, as well
as against human arginase and a battery of anti-targets, in order to select and profile the final set of
flavonoids with desired features that may help in the discovery and development of compounds to
treat leishmaniasis.
2. Results
2.1. EIIP/AQVN Filter
The virtual screening (VS) protocol in this paper was based on the application of sequential
filters to select candidate anti-leishmanial arginase inhibitors. Previously it was shown for
targets in different infectious diseases (HIV, Ebola virus, malaria, bacterial infections) that
small molecules with similar AQVN and EIIP values interact with the common therapeutic
target [24–26]. This resulted in establishing criteria for virtual screening of molecular libraries
for compounds with similar therapeutic properties [24,27]. In the series of analysis to be
reported here, first, we selected the training set encompassing 24 anti-leishmanial arginase
inhibitors from the ChEMBL Target Report Card of Leishmania amazonensis arginase inhibitors
(https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL3108635) [28]. 18 of those entries had IC50
values that were used for the building of QSAR models. Out of all the compounds presented in Figure 1,
21 of them are present inside the extended active domain (representing 87.5% of the total) with AQVN
and EIIP values within intervals of (3.13–3.58) and (0.09–0.134), respectively. A core group domain was
selected with AQVN and EIIP values within the intervals of (3.25–3.42) and (0.12–0.134), respectively, as
a criterion for the selection of compounds representing candidate anti-leishmanial arginase inhibitors.
By applying EIIP/AQVN-based virtual screening using this criterion, 200 flavonoids were chosen
out of the total 5679 compounds from the MetIDB database (www.metidb.org) [29] as candidates for
anti-leishmanial arginase inhibitors.
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EIIP (0.000–0.116) EIIP/AQVN domain of homologous distribution of >90% compounds from the 
PubChem Compound Database [30]. Statistics: Extended active group—inside the active wider 
domain: 21 (87.5%), outside the active wider domain: 3 (12.5%); Core active group—inside the active 
domain: 12 (50%), outside the active domain: 12 (50%). 
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Compound Dat b se [30]. Statistic : Extended active group—inside the active wider domain:
21 (87.5%), outside the active wider domain: 3 (12.5%); Core active group—inside the active domain:
12 (50%), outside the active doma n: 12 (50%).
In the previously reported EIIP/AQVN distribution of compounds from the PubChem
database (http://www.ncbi.nlm.nih.gov/pccompound) it has been found that 92.5% of compounds
are homogenously distributed within EIIP and AQVN intervals (0.00–0.11 Ry) and (2.4–3.3),
respectively [25]. This domain of the EIIP/AQVN space, encompassing the majority of known
chemical compounds was marked as a “basic EIIP/AQVN chemical space” (BCS). The majority of
the core active group of candidate anti-leishmanial arginase inhibitors belongs to the rare chemical
compounds that are out of BCS. The proposed EIIP/AQVN VS criteria suggest that testing only a
fraction of the compounds belonging to the core active group EIIP/AQVN domain out of a large set of
available molecules has a higher chance of being effective against leishmanial arginase than testing
compounds with any EIIP/AQVN values. The specificity of the proposed criterion for the selection of
compounds representing candidate anti-leishmanial arginase inhibitors is reflected in the fact that this
part of AQVN/EIIP space contains only 3% of all chemicals.
2.2. 3D-QSAR Model Building
Ten partial least squares (PLS) variables in the arginase inhibitors’ model represent the most
significant molecular properties for activity, where there is a negative contribution of variables 13, 199,
266, 428, 491, and positive contributions originating from variables 143, 171, 179, 266, 405, and 421
(Table 1, Figures 2 and 3). Since R2 values peaked at LV3, a model using three latent variables was
used. Tests using scrambled data further validated the model since they had a large influence on the
quality of the PLS model, resulting in much lower R2 values and negative Q2a values. Also, fractional
factorial design (FFD) convergence was achieved with a much lower number of variables. The tests
are shown in the Tables S1–S5.
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Table 1. Ten most significant PLS variables for Leishmania arginase inhibitors’ QSAR model.
Variable
Number Type Distance
Latent Variable
(LV5) Values Regions (see Figure 3)
1 13 DRY-DRY 5.20–5.60 ´0.1793 Distance between two aromatic rings A and C.
2 266 DRY-N1 2.40–2.80 ´0.2333 C3 atom from B ring and carbonyl O10 or carbonylO17 atom.
3 405 O-N1 16.40–16.80 0.2214
Carbonyl oxygen of OAc at position 1, ring C, and
OH oxygen atom, position 14, ring A, or C5 ring
C-CH2OH oxygen in glucose residue R2 , present
only in CHEMBL 3109443, 361362 and 250450.
4 199 TIP-TIP 17.20–17.60 ´0.4547 C6-C15 methyl groups.
5 428 O-TIP 4.80–5.20 ´0.2121 Ring A, distance between CH3 group C14 andnearest OH group C15.
6 143 N1-N1 15.60–16.00 0.3729 Distance between oxygens on A and C rings C14–C5.
7 421 O-TIP 2.00–2.40 0.2867 Distance between H atom and O curvature on thesame OH group on ring A C2 position.
8 491 N1-TIP 9.20–9.60 ´0.1997 Distance between link O atom, ring B or hexose ringand CH3 group curvature on ring A O10–C14.
9 171 TIP-TIP 6.00–6.40 0.2737 Distance between two curvature probes over twoneighbor OH groups in ring A C13–C14.
10 179 TIP-TIP 9.20–9.60 0.3568 Distance between two curvature probes over twoneighbor OH groups in ring C C6–C4.Molecules 2016, 21, 589 5 of 15 
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Variable (Var) 13 is related to the distance between two aromatic ring probes; its negative
contribution by a relative small distance suggests the presence of two close hydrophobic aminoacid
residues (or pocket), which form aromatic interactions with the molecule, and any deviation from
the ideal distance contributes negatively to the binding energy and thus, to the experimental activity.
Var 266 refers to the distance between aromatic ring and hydrogen bond acceptor, and its negative
contribution on such a short distance indicates the presence of a hydrogen bond donor aminoacid
residue close to a hydrophobic one. Due to the particularities of hydrogen bonding, small deviations
of distance and bond angles negatively affect the energy of interaction. Var 405 corresponds to the
distance between hydrogen bond acceptor and donor atoms on counter sides of a molecule. The longer
this distance, the higher the activity for such compound, which indicates there is a wide binding
site in the receptor. Var 199 corresponds to the curvature of a molecule; the negative contribution
is due to steric effects of protein—ligand interactions. Var 428 represents the curved surface point
of molecule and its nearest hydrogen bond donor, whose effect is also steric. Var 143 represents the
distance between two hydrogen bond donors on counter sides of the molecule. Its physicochemical
meaning is similar to Var 405. Var 421, contrary to Var 428, has a positive contribution for the distance
between hydrogen bond donor and point on the curved surface of the same atom, and is correlated
with activity. Var 419 has a similar physicochemical effect as Var 428. Var 171 and 179 are related
to the curvature of two close hydrogen bond donor (OH) groups and therefore, provide a positive
contribution to experimental activity. Some of the variables are presented on Figure 4a,b, and shown
on the least active compound and the most active compound.
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scores around compounds from the model (Figure 5), and (2) best ranking by predicted pIC50 values 
(Table 2). This filtering gave ten candidates which were used for docking into the Leishmania arginase 
structure model, the human arginase structure, and the off-target affinity calculations (see Table S7). 
 
Figure 5. PLS scores of 200 candidates in the Leishmania arginase 3D QSAR model. Red: candidates, 
black: 18 Leishmania arginase inhibitors. 
Figure 4. (a) The most active compound (CHEMBL3109443); and (b) the least active compound
(CHEMBL3109440) in the Leishmania arginase model with PLS variables. Green dots: TIP probes,
yellow dots: DRY probes, blue dots: N1, red dots: O probes. Lines that connect dots are variables, such
as DRY—DRY, TIP—TIP, N1—TIP etc.
Based on these QSAR properties, the activities of selected candidates were calculated and in order
to maintain molecular similarity, PLS scores were monitored, and so the compounds with the best
predicted pIC50 values were selected.
2.3. 3D QSAR Filtering
The 200 molecules filtered after EIIP criteria were subjected to prediction of their activity using
the above described Leishmania arginase 3D-QSAR model. The two criteria for selection were: (1) PLS
scores aro nd c mpounds from the model (Figure 5); and (2) best ranking by predicted pIC50 values
(Table 2). This filtering gave ten candidates which were used for docking into the Leishmania arginase
structure model, the human arginase structure, and the off-target affinity calculations (see Table S7).
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Table 2. List of docked compounds into Leishmania arginase homology model (L.A.) and human arginase crystal structure (H.A.) with QSAR calculated pIC50 values
for L.A., docking and MM/GBSA energies, and list of interacting aminoacid residues with L.A.
ID Predicted L.A. pIC50
L.A. Vina, Glide, and
Autodock 4 Scores,
MM/GBSA Energy (kcal/mol)
List of Aminoacid Residues Included in Interactions
H.A. Vina, Glide, and
Autodock 4 Scores,
MM/GBSA Energy (kcal/mol)
13 5.777 ´7.6, ´5.53, ´4.88, ´30.80 His28(H), Thr257(A), Asn143(H), Asp141(H), His139(A), Ala192(A) ´6.4, ´4.40, ´4.77, ´32.18
22 5.667 ´6.8, N/A, ´4.51, N/A Asn143(H), Asp141(H), His139(A), Val259(A) ´6.5, ´4.83, ´3.82, ´36.08
28 5.167 ´6.6, ´5.16, ´4.75, ´32.15 Asn143(H), His139(A), Thr257(A) ´6.0, ´4.07, ´3.98, ´31.69
38 5.054 ´7.0, ´5.14, ´4.01, ´35.12 Asp141(H), Asn152(H), Thr257(A), Asp194(H) ´6.9, ´5.35, ´4.60, ´38.47
39 5.465 ´6.8, ´5.23, ´4.59, ´39.11 Ser150(H), Asn143(H), Asp194(H), Ala192(A), Thr257(A) ´6.5, ´4.09, ´5.19, ´24.99
42 5.738 ´6.6, ´5.61, ´5.08, ´36.63 His139(A), Asn152(H), Thr257(A) ´6.8, ´3.84, ´4.01, ´32.88
50 5.122 ´6.3, ´5.04, ´4.32, ´49.23 Ser150(H), Asn152(H), His139(A), Val259(A), Ala192(A) ´7.2, ´3.96, ´4.35, ´18.30
56 5.283 ´6.6, ´5.64, ´4.32, ´35.87 Asn152(H), His154(A), His139(A), Asp141(H), Val259(A) ´6.0, ´5.38, ´4.15, ´33.92
59 5.204 ´7, ´4.88, ´5.59, ´32.81 Asn143(H), Glu197(H), Thr257(A), His139(A) ´6.7, ´5.61, ´4.44, ´32.44
64 5.673 ´6.7, ´4.04, ´4.39, ´40.30 Ser150(H), His139(A), Ala192(A), Val259(A) ´6.0, N/A, ´3.89, N/A
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black: 18 Leishmania arginase inhibitors.
2.4. Arginase Docking
Ten compounds were docked into the Leishmania arginase model structure, and their binding
energies and interactions are presented in Table 2. From the binding energy values, the best three
proposed compounds are 13, 39, and 22. Regarding the protein-ligand interactions formed, the binding
pattern shows very good agreement to the PLS model. Most compounds had stronger interactions
with the Leishmania arginase than to the human arginase. The only exceptions were 8 and 59 for Glide;
42 and 50 for Vina; 38, 39, and 50 for Autodock 4, and 13 and 38 for Molecular Mechanics/Generalized
Born Solvent Surface Area (MM/GBSA). The consensus using all four values gave all compounds
except 38 having stronger values for Leishmania than for human arginase. Based on this, the compounds
show predicted moderate specificity.
Variables can be easily correlated with binding site amino acid positions (Figure 6), as there are
only two types of interactions, hydrophilic, originating from Asn, Ser and Thr, and hydrophobic
(named “aromatic”), from His, Val and Ala.
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Figure 6. The binding site of Leishmania arginase in the homology model, with the most important
residues for interaction listed.
The aminoacid residues shown in Figure 6 are also those used in the binding mode by the known
inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) in Leishmania arginase structure 4iu0, and also
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interact with compound 39. The docking pose of the best candidate compound, 39, is presented
in Figure 7.
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arginase homology model with marked intermolecular interactions. Green lines: hydrogen bonds,
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Pairs of hydrophobic aminoacids correspond to DRY-DRY variables, hydrophobic-hydrophilic
to DRY-N1, N1-TIP, O-TIP. Pairs of hydrophilic interactions correspond to N1-N1 and O-N1, while
variables TIP-TIP correspond to mixed origins of molecule curvature, either from hydrophobic or
hydrophilic groups, and distances from Table 1 correspond to mutual positions of aminoacids in the
binding site and the strength of ligand interactions with them, depending on their fit to the binding
site shape.
2.5. Anti-Target Interaction Matrix
The top ten compounds from the filtering were then assessed against the anti-target battery. The
results of the docking of all the final compounds against the battery of five anti-targets and three
docking programs are shown in Figure 8 (full table of docking scores Table S8).
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There was broad general agreement between the three docking programs. None of the compounds’
binding score surpassed that of the threshold for CYP P450 2a6, for any docking program, which
may be an indication of the relative size of the ligands. There were more interactions found with the
anti-targets SULT and CYP P450 3a4. Compound 13 had the highest combined score, while several
compounds: 28, 39, and 56, had low interactions; lower than 3.0 for any docking program.
3. Discussion
Leishmanial arginase, the most examined enzyme in studies involving flavonoid compounds
as enzymatic inhibitors for Leishmania [18], is essential for the survival of the parasite [11] and
is also dissimilar from the mammalian target [10]. Therefore, targeting arginase with flavonoids
represents a promising therapeutic strategy for anti-leishmanial treatment. To select flavonoid
candidate anti-leishmanial arginase inhibitors, the virtual screening protocol in our study was based
on the sequential application of filters. Results of the application of VS based on the EIIP/AQVN
approach has shown that the domain encompassing core compounds is highly specific. This part of
AQVN/EIIP space contains only 3% of all chemicals.
One highly ranked flavonoid from our study—ent-epicatechin 3-O-gallate (compound 13)—has
indeed documented good inhibitory activity on the growth of Leishmania mexicana promastigotes
using methanol extracts of Byrsonima crassifolia bark that contain the referred flavonoid (as reported in
KNApSAcK Databases) [31]. The KNApSAcK Family of databases is an Integrated Metabolite–Plant
Species Databases with systematically organized relationships between metabolites and their biological
origins based on literature data [32]. As the active site in arginase of different strains of Leishmania is
conserved [10], it could be assumed that the selected candidate inhibitors may have potential to inhibit
arginase function in all Leishmania strains.
The proposed compounds must also be evaluated for selectivity against human arginase. The
anti-target results indicate that the interaction of the proposed candidate compounds with the
anti-targets is moderate. It is indeed likely that the desired interaction is precisely a moderate one,
neither completely absent (indicating low ability to be metabolized), or too strong and too many
interactions that may indicate lability and/or undesired interactions. The flavonoid nature of the
compounds may make them ready to be metabolized.
4. Materials and Methods
4.1. Ligand Data: Sources, Curation, Processing
The collection of compounds was downloaded from the MetIDB database as standard InChI
codes [29]. MetIDB is a reference database of experimental and predicted 1H NMR spectra of
6000 flavonoids. Containing a web-based interface, this database provides various interfaces to
the data and provides data-mining possibilities. The MetIDB database (www.metidb.org) [29] provides
a platform for flavonoids, for their storage and retrieval of 3D chemical structures, 1H NMR spectra,
and spectral parameters of fully annotated spectra. The InChI Key was used as a primary key.
In addition to the InChI Key, each compound was characterized by InChI Code, chemical formula,
exact monoisotopic mass, proton chemical shifts, and where possible, common name and CAS number
were also added. The virtual screening protocol reported in this study was based on the application of
sequential filters. First we have applied the EIIP/AQVN filter.
4.2. EIIP/AQVN Filter
Specific recognition and targeting between interacting biological molecules at distances > 5 Å
are determined by the average AQVN and the EIIP [33] derived from the general model
pseudopotential [34]:
EIIP “ 0.25 Z* sinp1.04piZ*q (1)
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where Z* is the average quasi-valence number (AQVN) determined by:
Z* “
ÿ
mpni Zi{Nq (2)
where Zi is the valence number of the ith atomic component, ni is the number of atoms of the ith
component, m is the number of atomic components in the molecule, and N is the total number of atoms.
EIIP values are calculated according to Equations (1) and (2) and are expressed in Rydberg units (Ry).
Among 3300 currently used molecular descriptors, AQVN and EIIP represent the unique physical
properties characterizing the long-range interactions between biological molecules [33]. A strong
connection has been demonstrated between the EIIP and AQVN of organic molecules and their
biological activity (mutagenicity, carcinogenicity, toxicity, antibiotic and cytostatic activity, etc.) [35].
4.3. 3D QSAR
In order to build a 3D QSAR model for compound activity prediction, 18 compounds with
IC50 activities against Leishmania amazonensis targeting arginase (Target ID CHEMBL3108635) were
downloaded from the ChEMBL database (Table S1) [28]. All compounds were converted to sdf format
and then imported. Compounds were imported into the Pentacle QSAR software [36], protonated at
pH 7.4, and oriented according to the principal moments of inertia. IC50 values were converted to
pIC50 and used as activities. Standard GRIND descriptors were calculated [36,37], based on molecular
interaction field (MIF) probes: DRY (representing hydrophobic interactions), N1 (representing neutral
flat NH like in amide, as hydrogen bond donor), O (sp2 carbonyl oxygen, representing hydrogen
bond acceptor), TIP (molecular shape descriptor) and the following principal components analysis
(PCA) and PLS models were constructed. The number of PC components in the PCA model was
five, and in PLS the number of latent variables (LV) was 3. Fractional factorial design (FFD) variables
selection was repeated until R2 and Q2 values of the PLS model converged. Finally, out of 520 PLS
components, 114 were selected after 19 optimizations. R2acc was 0.99 and Q2acc was 0.89. Statistics
of the PLS model are presented in Table 3. The model was saved for prediction. The EIIP filtered
compounds were loaded into the model and their pIC50 activities were calculated. Calculations were
done in Pentacle 1.05 [36–38].
Table 3. Statistics of PLS model for Leishmania amazonesis arginase. Legend: SSX—X
variable explanation; SSXacc—X accumulation; SDEC—Standard Deviation of Error of Calculation,
SDEP—Standard Deviation of Error of Prediction, R2acc—R2 accumulation; Q2acc—Q2 accumulation.
Number of Latent Variables SSX SSXacc SDEC SDEP R2 R2acc Q2acc
1 28.31 28.31 0.45 0.61 0.64 0.64 0.34
2 12.94 41.25 0.13 0.33 0.33 0.97 0.81
3 7.95 49.20 0.08 0.25 0.02 0.99 0.89
4.4. Molecular Docking for Human and Leishmania Arginase
Docking experiments into a Leishmania amazonensis arginase model and into a human arginase
crystal protein structure were also performed. A homology model of arginase, earlier constructed, was
built on a template of the crystal structure of Leishmania mexicana arginase in complex with inhibitor
ABH (PDBID 4iu0) [39] (obtained from the Protein Model Portal [40], query O96394). Evaluation of
the homology model structure using MODELER (https://salilab.org/modeller) resulted in a GA341
score of 1.0, which scores the reliability of a model derived from statistical potentials and predicts it to
be reliable when the model score is higher than the pre-specified cutoff of 0.7. A reliable model has a
probability of the correct fold >95%, where a fold is correct when at least 30% of its Cα atoms superpose
within 3.5 Å of their correct positions. The human arginase protein structure was downloaded from the
PDB (2aeb) [39]. Docking was performed with Autodock Vina [41], Glide SP [42], post-processed with
MM/GBSA calculations [43], and with Autodock 4 [44]. The grid box was set to span all important
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residues, according to the previously reported binding site [20]. Water molecules were conserved since
they may be important for protein-ligand binding [45–49]
4.5. Anti-Target Set
The anti-target battery consisted of three different docking programs and their different scores:
Glide XP (XP) [40], Autodock 4 (AD4) [42], and Autodock Vina (Vina) [39], and the proteins
pregnane-X-receptor (PXR), sulfotransferase (SULT), cytochromes (CYP) P450 2a6, 2c9, and 3a4. Their
structures had resolutions better than 2.6 Å and were downloaded from the PDB (r. 1m13, 2a3r, 1z10,
1og5, 1tqn) [39]. The binding score recorded by their co-crystallized ligand was used as the threshold
for determining strong interaction, corresponding to ´7.7, ´6.3, ´7.6, ´8.7, and ´7.5 with XP; ´12.5,
´7.5, ´6.8, ´9.4, and ´7.5 for AD4; and ´10.3, ´6, 08.5, ´10, and ´7.5 for Vina, which corresponded
well with other known inhibitors [22,23]. In order to provide a rough estimate of the interaction, the
binding scores were converted to interaction codes represented as:
Score “ 0.0 if∆G´∆Gref ą 0.5 (3)
Score “ 0.5 if |∆G´∆Gref| ď 0.5 (4)
Score “ 1.0 if∆G´∆Gref ă ´ 0.5 (5)
where ∆Gref is the dock score of the protein with co-crystallized active reference ligand, and ∆G is
the dock score for a ligand bound to that protein binding site. These interactions were then shaded
white, grey, and black, respectively. Their interaction scores can then be summed across each docking
program, across all three docking programs, or the average be taken, or the interaction for a series of
compounds with specific proteins.
5. Conclusions
Natural compounds present an interesting treatment option against leishmaniasis. A series of
flavonoid compounds was filtered according to their average qausi-valence number, electron-ion
interaction potential, 3D-QSAR with a homology model of Leishmania arginase, and docking to this
model in addition to human arginase. An inhibitor was recovered among the actives. The ten most
promising candidate compounds were assessed in their interaction profile against a series of five
proteins as anti-targets involved in the human metabolism of substances. The compounds present
favourable interaction profiles with arginase and against the anti-targets that suggest the compounds
may be useful for further investigations and may be better starting points than screening compounds
at random. The present results will be confirmed by experimental enzyme inhibition studies in further
investigations. These will ultimately show whether these flavonoids are active for several strains
and specific, and that they can be useful starting points for the design of safe, easily sourceable,
small-molecule compounds for treating the neglected tropical disease leishmaniasis and diminish its
burden on populations and healthcare systems.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/
21/5/589/s1.
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